Top Buy Stocks for June 16: AMDA, CLF, CTIC, TGT, ZIOP

NASDAQ: AMDA (Amedica Corp)

Amedica Corporation  announced its expected participation in the 2015 LD MICRO Invitational Conference on June 3, 2015 at 10:00 AM Pacific Time in Los Angeles, CA.

AMDA  has closed at $0.475, its traded Volume was 15643.9K shares, AMDA opened the Day at $0.41, it made an intraday Low of $0.4, and an intraday High of $0.497. AMDA’s close price is above its Short term MA, short term MA is above mid-term, and below long term MA. AMDA (Amedica Corp) 52-week High is $4.95, 52-week Low is: $0.204, it has supports at $0.31 and $0.2, resistances at $0.49 and $0.57. AMDA’s earning is $-1.9 per share, Next quarter estimated EPS is $-0.03, current year estimated EPS is $-0.24. Its PE ratio is 0. Overall, this stock is rated BUY today.

NYSE: CLF (Cliffs Natural Resources Inc)

Wall Street analysts expect Cliffs Natural Resources Inc. to report earnings per share of $-0.11 for the current fiscal quarter.

CLF has closed at $5.46, its traded Volume was 5806.58K shares, CLF opened the Day at $5.42, it made an intraday Low of $5.33, and an intraday High of $5.59. CLF’s close price is above its Short term MA, short term MA is below mid-term, and below long term MA. CLF (Cliffs Natural Resources Inc) 52-week High is $17.999, 52-week Low is: $4.12, it has supports at $4.53 and $3.76, resistances at $5.96 and $6.86. CLF’s earning is $0 per share, Next quarter estimated EPS is $0, current year estimated EPS is $-1.63. Its PE ratio is 0. Overall, this stock is rated BUY today.

NASDAQ: CTIC (Cell Therapeutics)

CTI BioPharma Corp. today announced findings from an investigator-sponsored Phase 2 trial in patients with either primary (de novo) acute myeloid leukemia (AML) or AML that has evolved from myelodysplastic syndrome (MDS). Results showed the combination of tosedostat with low dose cytarabine/Ara-C (LDAC) resulted in an overall response rate (ORR) of 54 percent in elderly patients with AML – with 45 percent of patients achieving durable complete responses (CR).

CTIC has closed at $2.13, its traded Volume was 5126.82K shares, CTIC opened the Day at $2.09, it made an intraday Low of $2.05, and an intraday High of $2.14. CTIC’s close price is above its Short term MA, short term MA is above mid-term, and below long term MA. CTIC (Cell Therapeutics) 52-week High is $3.11, 52-week Low is: $1.65, it has supports at $1.95 and $1.64, resistances at $2.46 and $2.87. CTIC’s earning is $-0.61 per share, Next quarter estimated EPS is $0, current year estimated EPS is $0.49. Its PE ratio is -3. Overall, this stock is rated BUY today.

NYSE: TGT (Target Corp)

Health Corporation (CVS) and Target Corporation (TGT) announced today that they have entered into a definitive agreement for CVS Health to acquire Target’s pharmacy and clinic businesses for approximately $1.9 billion.

TGT has closed at $80.45, its traded Volume was 6226.5K shares, TGT opened the Day at $80.42, it made an intraday Low of $80.02, and an intraday High of $81.09. TGT’s close price is above its Short term MA, short term MA is below mid-term, and above long term MA. TGT (Target Corp) 52-week High is $83.424, 52-week Low is: $55.564, it has supports at $78.8 and $75.95, resistances at $83.42 and $97.43. TGT’s earning is $-2.23 per share, Next quarter estimated EPS is $0, current year estimated EPS is $0. Its PE ratio is -36. Overall, this stock is rated BUY today.

NASDAQ: ZIOP (Ziopharm Oncology Inc)

Ziopharm Oncology Inc has determined the final distribution ratio relating to its previously announced distribution of all of its 17,830,305 shares of ZIOPHARM Oncology, Inc. common stock on or about June 12, 2015, the distribution date, as a pro rata dividend on shares of Intrexon common stock, and on warrants to purchase shares of Intrexon common stock (“Warrants”), outstanding on June 4, 2015, the record date.

ZIOP has closed at $10.72, its traded Volume was 5524.04K shares, ZIOP opened the Day at $9.56, it made an intraday Low of $9.35, and an intraday High of $10.75. ZIOP’s close price is above its Short term MA, short term MA is below mid-term, and below long term MA. ZIOP (Ziopharm Oncology Inc) 52-week High is $14.4, 52-week Low is: $2.31, it has supports at $9.96 and $8.63, resistances at $12.13 and $14.16. ZIOP’s earning is $-0.96 per share, Next quarter estimated EPS is $0, current year estimated EPS is $0. Its PE ratio is -11. Overall, this stock is rated BUY today.

About the Author

has written 14551 stories on this site.

Copyright © 2012 Nine Stocks